Name:
Institution:
Type:
PI
Grant Award Details
Hematopoietic Stem Cell Gene Therapy for XCGD
Grant Type:
Grant Number:
CLIN1-13315
Project Objective:
- Goal of this project is to develop autologous HDSC gene therapy for X-CGD by LV-mediated gene modification of HSPC to restore physiologic gp91 expression. Scope of the work includes completion of all IND-enabling activities required to file a fully supported IND to start a Phase 1 clinical trial.
Investigator:
Disease Focus:
Blood Disorders
X-linked Chronic Granulomatous Disease
Human Stem Cell Use:
Adult Stem Cell
Award Value:
$3,999,959
Status:
Active
Grant Application Details
Application Title:
- Hematopoietic Stem Cell Gene Therapy for XCGD
Public Abstract:
Therapeutic Candidate or Device
Hematopoietic stem and progenitor cells collected from X-CGD patients modified with a highly regulated lentiviral vector
Indication
X-linked Chronic Granulomatous Disease
Therapeutic Mechanism
Lentiviral vector (LV) modification of autologous hematopoietic stem and progenitor cells (HSPCs) to restore physiologic gp91phox expression. We have developed a next-generation LV designed by bioinformatic-guided screening of enhancer/promoter elements from the human CYBB gene to restore physiologically regulated expression of gp91phox protein.
Unmet Medical Need
Allogeneic transplant, while curative, is not available to patients without a matched donor, an issue that is particularly exacerbated for patients from ethnic minorities.
Project Objective
Submit an IND to initiate a Phase I/II trial
Major Proposed Activities
- Complete CMC requirements (vector production and cell manufacturing)
- Complete toxicology studies (in relevant mouse model and cell culture systems)
- Initiate documentation required to open a PhaseI/II trial
Statement of Benefit to California:
This proposal uses the first product from our pipeline that creates highly regulated vectors. The resulting Phase I/II trial should demonstrate clinical superiority of our vector and provide a treatment for X-linked Chronic Granulomatous Disease. Moreover this trial will pave the way for other vectors in our pipeline to treat a range of primary immune deficiencies and other genetic blood diseases. This will result in improved patient care in the state of California and around the world.
